Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746389 | 1.00 | ALOX5 (0.36) | ALOX5IGF1RAAK1AOC3SSTR4 | |
| SCHEMBL1463909 | 0.84 | NPC1 (0.37) | ALOX5AAK1MEN1KMT2ATXNRD1 | |
| SCHEMBL1463908 | 0.84 | NPC1 (0.37) | ALOX5AAK1MEN1KMT2ATXNRD1 | |
| SCHEMBL1464057 | 0.84 | MEN1 (0.42) | ALOX5AAK1MEN1KMT2A | |
| SCHEMBL9962943 | 0.84 | MEN1 (0.42) | ALOX5AAK1MEN1KMT2A | |
| SCHEMBL3408772 | 0.83 | ALOX5 (0.41) | ALOX5IGF1RAOC3MEN1KMT2A | |
| SCHEMBL3408769 | 0.83 | ALOX5 (0.41) | ALOX5IGF1RAOC3MEN1KMT2A | |
| SCHEMBL3408775 | 0.83 | ALOX5 (0.41) | ALOX5IGF1RAOC3MEN1KMT2A | |
| SCHEMBL15784772 | 0.80 | ALOX5 (0.40) | ALOX5AAK1MEN1KMT2APYCR1 | |
| SCHEMBL1642464 | 0.77 | ALDH1A1 (0.33) | ALOX5AAK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | ALOX5 990/4885IGF1R 378/4885AAK1 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.